Polio vaccines are important to prevent the polio disease worldwide
Polio vaccines |
Polio vaccines are administered
at birth to induce mucosal immunity to the polio virus. The vaccine is
effective against all three serotypes of the disease. This method also
increases seroconversion rates. It also triggers mucosal protection before
enteric pathogens are able to infect the child. It is therefore recommended by
the WHO to administer a birth dose of OPV to infants in countries with a high
risk of poliomyelitis. The oral poliovirus (OPV) vaccine is the most common
vaccine used to eradicate polio in countries. It is easy to administer, is
cheap, and induces superior intestinal immunity. The primary difference between
the two types of vaccines is that OPV induces intestinal immunity, while IPV
induces high transmission immunity to the wild poliovirus. The advantages of
both types of vaccines are the same, although IPV is the preferred choice in
developed countries.
According to Coherent Market Insights the Polio
Vaccines Market Global Industry Insights, Trends, Outlook, and
Opportunity Analysis, 2022-2028.
Because poliomyelitis is a highly
infectious disease, it is imperative that children be immunized. There are 3
strains of the wild poliovirus in the United States. Therefore, it is important
for children to be immunized at a young age. The inactivated poliovirus vaccine
is based on three wild-type poliovirus strains. It is a live-attenuated vaccine
that has the advantage of being oral and not requiring needles. The vaccines
are more effective than inactivated ones, but both have their drawbacks.
Inactivated vaccines require regular re-administration and must be used by
children with weak immune systems. However, there is no reliable proof that
either vaccine is effective in the long term.
In the end, a new generation of polio vaccines may be able to eliminate the disease. Adjuvanted IPV type 2 with higher antigen content may provide a more effective primary immunogenicity against type 2. Researchers at Bilthoven Biologicals are developing a new version of m-IPV2 with 32 D-Ag units, which is four times the current dose of type 2 in trivalent IPV.
Comments
Post a Comment